John P. Leonard, MD, Weill Cornell Medicine

Exploring Emerging Data in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 23rd 2021

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Looking at the Big Picture in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 23rd 2021

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

Treating Patients Post CAR T Therapy

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 23rd 2021

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Optimal Approaches to Bridging Therapy in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 16th 2021

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

Evaluating CAR T Therapies in Lymphoma

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 16th 2021

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Recommendations for CAR T-Cell Therapy in R/R DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 9th 2021

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

Newer Approvals for Previously Treated DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 9th 2021

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

DLBCL: Approaches to Treating Patients Ineligible for Transplant

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 2nd 2021

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.

Data From the L-MIND Trial

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

August 2nd 2021

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

Recommendations for Second-Line Therapy in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

July 26th 2021

Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.

Managing Relapsed DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

July 26th 2021

Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.

Outlook for CNS Lymphoma

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

July 19th 2021

David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.

DLBCL: Approaching CNS Prophylaxis

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

July 19th 2021

A panel of experts explain how they approach CNS prophylaxis in DLBCL.

Treatment Considerations in DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

July 12th 2021

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

Treating Newly Diagnosed Patients With DLBCL

ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health

July 12th 2021

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

John P. Leonard, MD, of Weill Cornell Medicine

Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma

ByJohn P. Leonard, MD, Weill Cornell Medicine,John Leonard, MD

July 7th 2021

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

Closing Thoughts on Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Improving Outcomes in Patients With R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Emerging Therapies for R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Safety and Efficacy of Oral Agents in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Prognosis of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Standard of Care for Treatment of DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Dr. Leonard on the FDA Approval of Tazemetostat in Follicular Lymphoma

ByJohn P. Leonard, MD, Weill Cornell Medicine

June 18th 2020

John P. Leonard, MD, discusses the FDA approval of tazemetostat in follicular lymphoma.

Dr. Leonard on AUGMENT Trial Results in Non-Hodgkin Lymphoma

ByJohn P. Leonard, MD, Weill Cornell Medicine

December 3rd 2018

John P. Leonard, MD, associate dean for clinical research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, discusses the key takeaway from the phase III AUGMENT trial, a randomized study of lenalidomide (Revlimid) plus rituximab (Rituxan) (R2) versus rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma, during the 2018 ASH Annual Meeting.